Inflammatory Bowel Disease is under clinical development by Torrent Pharmaceuticals and currently in Phase II for Inflammatory Bowel Disease. According to GlobalData, Phase II drugs for Inflammatory Bowel Disease have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Inflammatory Bowel Disease’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Inflammatory Bowel Disease overview

Small molecule is under development for the treatment of inflammatory bowel disease. The therapeutic drug candidate is a new chemical entity.

Torrent Pharmaceuticals overview

Torrent Pharmaceuticals (Torrent) is a pharmaceutical company. The company specializes in various therapeutic areas. Its primary focus includes cardiovascular, central nervous system, gastrointestinal, diabetology, anti-infective, urology, and pain management. The company also has a presence in nephrology, cancer, gynecology and pediatric business. It offers contract manufacturing services for the formulation of active pharmaceutical ingredients (APIs). Torrent operates its manufacturing units in India. The company has a presence through its operations in the US, the UK, Germany, Russia, Brazil, Mexico, the Philippines and other major markets. Torrent is headquartered in Ahmedabad, Gujarat, India.

For a complete picture of Inflammatory Bowel Disease’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.